BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31043123)

  • 1. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
    Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
    J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
    Anselmi M; Hub JS
    Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
    Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
    J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of demethylincisterol A
    Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
    Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
    Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
    Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
    Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wu J; Li W; Zheng Z; Lu X; Zhang H; Ma Y; Wang R
    J Biomol Struct Dyn; 2021 Mar; 39(4):1174-1188. PubMed ID: 32036779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
    Anselmi M; Hub JS
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new small molecule allosteric SHP2 inhibitor through pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation studies, synthesis and
    Mitra R; Kumar S; Ayyannan SR
    J Biomol Struct Dyn; 2023 Dec; ():1-20. PubMed ID: 38095360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
    Hartman Z; Geldenhuys WJ; Agazie YM
    J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Front Chem; 2020; 8():597495. PubMed ID: 33330386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.